Trial Profile
Phase II Study of AZD0530 (NSC 735464) in Patients With Previously Treated Metastatic Colorectal Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Saracatinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 14 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 23 Mar 2011 Planned End Date changed from 1 Feb 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
- 09 Jun 2010 Planned end date changed from 1 Apr 2008 to 1 Feb 2011 as reported by Clinical trials.gov.